MX2013008367A - Firmas de esxpresion genetica de cancer de colon y metodos de uso. - Google Patents

Firmas de esxpresion genetica de cancer de colon y metodos de uso.

Info

Publication number
MX2013008367A
MX2013008367A MX2013008367A MX2013008367A MX2013008367A MX 2013008367 A MX2013008367 A MX 2013008367A MX 2013008367 A MX2013008367 A MX 2013008367A MX 2013008367 A MX2013008367 A MX 2013008367A MX 2013008367 A MX2013008367 A MX 2013008367A
Authority
MX
Mexico
Prior art keywords
colon cancer
gene expression
methods
cancer gene
expression signatures
Prior art date
Application number
MX2013008367A
Other languages
English (en)
Inventor
Denis Paul Harkin
Vitali Proutski
Julie Black
Peter Kerr
Richard Kennedy
Andreas Winter
Timothy Davison
Max Bylesjo
Vadim Farztdinov
Claire Wilson
Robert James Holt
Original Assignee
Almac Diagnostics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almac Diagnostics Ltd filed Critical Almac Diagnostics Ltd
Publication of MX2013008367A publication Critical patent/MX2013008367A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se provee una firma de expresión genética de cáncer de colon, microarreglos que la incluyen y métodos de uso de la firma de expresión genética de colon. La firma de expresión genética es especialmente útil para determinar la prognosis de un paciente diagnosticado con cáncer de colon, tal como cáncer de colon etapa II. La firma genética descrita en la presente es también útil para determinar la efectividad de resección quirúrgica con o sin quimioterapia adyuvante y determinar la posibilidad de recurrencia de cáncer en pacientes con cáncer de colon.
MX2013008367A 2011-01-25 2012-01-25 Firmas de esxpresion genetica de cancer de colon y metodos de uso. MX2013008367A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161435922P 2011-01-25 2011-01-25
PCT/US2012/022594 WO2012103250A2 (en) 2011-01-25 2012-01-25 Colon cancer gene expression signatures and methods of use

Publications (1)

Publication Number Publication Date
MX2013008367A true MX2013008367A (es) 2013-08-12

Family

ID=46581385

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013008367A MX2013008367A (es) 2011-01-25 2012-01-25 Firmas de esxpresion genetica de cancer de colon y metodos de uso.

Country Status (14)

Country Link
US (1) US10196691B2 (es)
EP (1) EP2668296B1 (es)
JP (1) JP2014509189A (es)
KR (1) KR20140006898A (es)
CN (1) CN103403543B9 (es)
AU (1) AU2012209074A1 (es)
BR (1) BR112013018924A2 (es)
CA (1) CA2825218A1 (es)
EA (1) EA201391074A1 (es)
IL (1) IL227643A0 (es)
MX (1) MX2013008367A (es)
SG (1) SG192108A1 (es)
WO (1) WO2012103250A2 (es)
ZA (1) ZA201305024B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10787701B2 (en) 2010-04-05 2020-09-29 Prognosys Biosciences, Inc. Spatially encoded biological assays
RS54482B1 (en) 2010-04-05 2016-06-30 Prognosys Biosciences, Inc. SPATIAL CODING BIOLOGICAL TESTING
US20190300945A1 (en) 2010-04-05 2019-10-03 Prognosys Biosciences, Inc. Spatially Encoded Biological Assays
GB201106254D0 (en) 2011-04-13 2011-05-25 Frisen Jonas Method and product
US20130074201A1 (en) * 2011-09-16 2013-03-21 The Johns Hopkins University Cancer-specific genetic rearrangements
DK3511423T4 (da) * 2012-10-17 2024-07-29 Spatial Transcriptomics Ab Fremgangsmåder og produkt til optimering af lokaliseret eller rumlig detektion af genekspression i en vævsprøve
EP4234716A3 (en) 2013-06-25 2023-12-06 Prognosys Biosciences, Inc. Methods for determining spatial patterns of biological targets in a sample
US9652722B1 (en) * 2013-12-05 2017-05-16 The Mathworks, Inc. Methods and systems for robust supervised machine learning
AU2015216886A1 (en) * 2014-02-17 2016-08-25 F. Hoffmann-La Roche Ag G-alpha, interacting vesicle associated protein (GIV) as a predictive marker in stage II colorectal cancer
WO2015155765A1 (en) * 2014-04-10 2015-10-15 Bio-Marcare Technologies Ltd. Methods and kits for identifying pre-cancerous colorectal polyps and colorectal cancer
EP3530752B1 (en) 2015-04-10 2021-03-24 Spatial Transcriptomics AB Spatially distinguished, multiplex nucleic acid analysis of biological specimens
CN108020672A (zh) * 2016-11-03 2018-05-11 中国医学科学院基础医学研究所 检测rhbdd1蛋白的elisa方法及试剂盒
WO2018107023A1 (en) * 2016-12-08 2018-06-14 Dana-Farber Cancer Institute, Inc. Metabolic profiling of fixed samples
CN107158388B (zh) * 2017-07-11 2021-03-23 上海市第一人民医院 MIIP pS303阻断剂在制备抗肿瘤药物中的应用
SG11202006974WA (en) * 2018-01-22 2020-08-28 Liquid Biopsy Res Llc Methods for colon cancer detection and treatment monitoring
US20210148912A1 (en) * 2018-04-12 2021-05-20 Board Of Regents, The University Of Texas System Biomarker for detecting cancer
JP2020028278A (ja) * 2018-08-24 2020-02-27 国立大学法人九州大学 被検体に生じるイベントを予測するための判別器の生成方法、及び前記判別器を用いた被検体の層別化方法
CN111321220A (zh) * 2018-12-14 2020-06-23 中国医学科学院肿瘤医院 用于检测直肠癌放化疗敏感性的组合物、微阵列和计算机系统
CN110079607B (zh) * 2019-04-04 2022-08-02 陕西师范大学 一种引物组、检测血液样品种属的方法及应用
EP3976820A1 (en) 2019-05-30 2022-04-06 10X Genomics, Inc. Methods of detecting spatial heterogeneity of a biological sample
CN116249785A (zh) 2020-06-02 2023-06-09 10X基因组学有限公司 用于抗原-受体的空间转录组学
AU2021283174A1 (en) 2020-06-02 2023-01-05 10X Genomics, Inc. Nucleic acid library methods
ES2981265T3 (es) 2020-06-08 2024-10-08 10X Genomics Inc Métodos para determinar un margen quirúrgico y métodos de uso del mismo
CN111951883A (zh) * 2020-08-04 2020-11-17 广东省第二人民医院（广东省卫生应急医院） 一种特征mRNA表达谱组合及结肠癌早期预测方法
CN115786518A (zh) * 2022-11-29 2023-03-14 广东医科大学附属医院 嗅素结构域家族蛋白4（olfm4）在结肠癌检测产品中的应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3481060D1 (de) 1983-09-02 1990-02-22 Molecular Biosystems Inc Oligonukleotid-polymer-tragsystem.
CA1323293C (en) 1987-12-11 1993-10-19 Keith C. Backman Assay using template-dependent nucleic acid probe reorganization
GB8810400D0 (en) 1988-05-03 1988-06-08 Southern E Analysing polynucleotide sequences
WO1990001069A1 (en) 1988-07-20 1990-02-08 Segev Diagnostics, Inc. Process for amplifying and detecting nucleic acid sequences
US5219727A (en) 1989-08-21 1993-06-15 Hoffmann-Laroche Inc. Quantitation of nucleic acids using the polymerase chain reaction
US5427930A (en) 1990-01-26 1995-06-27 Abbott Laboratories Amplification of target nucleic acids using gap filling ligase chain reaction
US5554501A (en) 1992-10-29 1996-09-10 Beckman Instruments, Inc. Biopolymer synthesis using surface activated biaxially oriented polypropylene
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
US5648211A (en) 1994-04-18 1997-07-15 Becton, Dickinson And Company Strand displacement amplification using thermophilic enzymes
AU2360195A (en) 1994-05-05 1995-11-29 Beckman Instruments, Inc. Oligonucleotide repeat arrays
JP3881009B2 (ja) 1994-07-15 2007-02-14 バイオメリオ・ベー・ベー 核酸増幅方法を改良するためのｒｎａポリメラーゼの使用
AT402203B (de) 1995-06-13 1997-03-25 Himmler Gottfried Dipl Ing Dr Verfahren zur transkriptionsfreien amplifizierung von nucleinsäuren
US5716784A (en) 1996-02-05 1998-02-10 The Perkin-Elmer Corporation Fluorescence detection assay for homogeneous PCR hybridization systems
CA2255774C (en) 1996-05-29 2008-03-18 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions
US5985567A (en) 1997-08-15 1999-11-16 Beckman Coulter, Inc. Hybridization detection by pretreating bound single-stranded probes
US6013789A (en) 1998-02-20 2000-01-11 Beckman Coulter, Inc. Covalent attachment of biomolecules to derivatized polypropylene supports
US20010055596A1 (en) 2000-03-24 2001-12-27 Meagher Madeleine Joy Compositions and methods for therapy and diagnosis of colon cancer
EP1534739A4 (en) * 2002-01-18 2006-05-31 Bristol Myers Squibb Co IDENTIFICATION OF POLYNUCLEOTIDES AND POLYPEPTIDES FOR PREDICTING THE ACTIVITY OF COMPOUNDS THAT INTERACT WITH TYROSINE KINASE PROTEINS AND / OR TYROSINE KINASE PROTEIN PATHWAYS
EP2314691A3 (en) 2002-11-14 2012-01-18 Dharmacon, Inc. Fuctional and hyperfunctional siRNA
US7250496B2 (en) 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
EP1603514A4 (en) 2003-01-24 2007-08-22 Bayer Pharmaceuticals Corp EXPRESSION PROFILES FOR THYROID CANCER AND APPLICATION METHOD
WO2005054508A2 (en) 2003-12-01 2005-06-16 Ipsogen Gene expression profiling of colon cancer by dna microarrays and correlation with survival and histoclinical parameters
KR20070052694A (ko) 2004-01-09 2007-05-22 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 유전자 발현을 위한 세포-유형-특이적 패턴
WO2005083128A2 (en) 2004-02-25 2005-09-09 University Of South Florida Methods for predicting cancer outcome and gene signatures for use therein
US20060195266A1 (en) 2005-02-25 2006-08-31 Yeatman Timothy J Methods for predicting cancer outcome and gene signatures for use therein
CA2569079A1 (en) 2004-06-03 2005-12-15 The Johns Hopkins University Methods of screening for cell proliferation or neoplastic disorders
CA2586201A1 (en) 2004-11-03 2006-05-11 Almac Diagnostics Limited Transcriptome microarray technology and methods of using the same
WO2007048074A1 (en) * 2005-10-21 2007-04-26 Genenews Inc. Method and apparatus for correlating levels of biomarker products with disease
NZ593228A (en) * 2006-01-11 2012-10-26 Genomic Health Inc Gene expression markers (inhba) for colorectal cancer prognosis
WO2007112330A2 (en) 2006-03-24 2007-10-04 Diadexus, Inc. Compositions and methods for detection, prognosis and treatment of colon cancer
US20100261169A1 (en) * 2007-01-29 2010-10-14 Shira Wallach Novel nucleotide and amino acid sequences, and methods of use thereof for diagnosis
NZ562237A (en) 2007-10-05 2011-02-25 Pacific Edge Biotechnology Ltd Proliferation signature and prognosis for gastrointestinal cancer
ES2610588T3 (es) * 2008-05-27 2017-04-28 Dako Denmark A/S Composiciones y métodos para la detección de aberraciones cromosómicas con tampones de hibridación novedosos
WO2010060055A1 (en) 2008-11-21 2010-05-27 Duke University Predicting cancer risk and treatment success

Also Published As

Publication number Publication date
JP2014509189A (ja) 2014-04-17
WO2012103250A3 (en) 2012-10-11
US10196691B2 (en) 2019-02-05
EP2668296A2 (en) 2013-12-04
NZ612471A (en) 2015-11-27
ZA201305024B (en) 2014-03-26
KR20140006898A (ko) 2014-01-16
US20140094379A1 (en) 2014-04-03
AU2012209074A1 (en) 2013-07-11
CA2825218A1 (en) 2012-08-02
BR112013018924A2 (pt) 2018-05-08
CN103403543A (zh) 2013-11-20
CN103403543B (zh) 2016-11-09
WO2012103250A2 (en) 2012-08-02
EP2668296A4 (en) 2015-09-02
IL227643A0 (en) 2013-09-30
EP2668296B1 (en) 2018-08-15
SG192108A1 (en) 2013-08-30
CN103403543B9 (zh) 2017-05-17
EA201391074A1 (ru) 2013-12-30

Similar Documents

Publication Publication Date Title
MX2013008367A (es) Firmas de esxpresion genetica de cancer de colon y metodos de uso.
EP2611941A4 (en) GENESIS OF CANCER DIAGNOSIS AND PROGNOSIS
PH12015501744A1 (en) Therapeutic and diagnostic target for cancer comprising dll3 binding reagents
WO2012006447A3 (en) Gene signatures for cancer prognosis
MX341734B (es) Biomarcadores para la prediccion de la eficacia de una inmunoterapia contra el cancer.
MX2013002084A (es) Biomarcadores y metodos de tratamiento.
EA201391114A1 (ru) Способы использования alk-ингибиторов
MX368513B (es) Métodos in vitro para el pronóstico, diagnóstico y diseño de una terapia de metástasis de cáncer de pulmón.
WO2012153187A3 (en) Markers for cancer prognosis and therapy and methods of use
MX2020009704A (es) Metodo para usar expresion genica para determinar la probabilidad de un desenlace clinico de cancer renal.
MX2014006404A (es) Metodos y kits para el pronostico del cancer colorrectal.
AU2012305327B2 (en) Polymer-type fluorescent molecule probe
WO2012170776A3 (en) Methods of determining a patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy
EP2598873A4 (en) BIOMARKERS OF PROSTATE CANCER AND METHODS USING THEM
TR201903026T4 (tr) S100a4 anti̇korlari ve bunlarin terapöti̇k kullanimlari.
WO2013028554A3 (en) Gene signatures for lung cancer prognosis and therapy selection
WO2011106541A3 (en) Diagnostic methods involving loss of heterozygosity
CL2013003324A1 (es) Composicion que comprende quimioterapia con paclitaxel y carboplatino y un oligonucleotido anti-clusterina; uso de la composición para el tratamiento de un paciente humano que padece cancer de pulmón.
MX2013006758A (es) Peptidos de union a hla derivados de moleculas antigenicas asociadas a la prostata y metodos de uso de los mismos.
EA201301265A1 (ru) Способ лечения солидных злокачественных опухолей, включая прогрессирующие или метастатические солидные злокачественные опухоли
EP3798316A3 (en) Genes and gene signatures for diagnosis and treatment of melanoma
WO2012138715A3 (en) Small molecule inhibitors of xbp1 splicing
WO2013081645A3 (en) Erbb3 mutations in cancer
WO2012109233A3 (en) Methods for predicting recurrence risk in breast cancer patients
TR201111743A2 (tr) Kanser tedavisinde kullanılmak üzere yağ bazlı nanotaşıyıcı sistemler.